October 29, 2026By OSV News OSV News Filed Under: Feature, News, World News NEWARK, N.J. (OSV News) — Cardinal Joseph W. Tobin of Newark has been found to have a kidney mass and is scheduled to undergo surgery on Oct. 29 to remove it, according…
Daily therapy with a non-vitamin K antagonist oral anticoagulant (NOAC) can dramatically lower the incidence of venous thromboembolism (VTE) in patients with cancer who are at moderate-to-high risk for developing a clot, according to the results of two new studies.
Oct 29, 2026, 16:37 ET Research investment targets lung cancer, asthma, COPD and emerging respiratory threats CHICAGO, Oct. 29, 2026 /PRNewswire/ -- Today, the American Lung Association Research Institute announced it has invested $21 million in research and related scientific activities. Over the last 10 years, the Lung…
Iovance stock sank after phase 2 Amtagvi lung cancer data. Read more here. Rasi Bhadramani/iStock via Getty Images - Iovance Biotherapeutics (IOVA) is down ~34% in Thursday trading after releasing data for two cohorts of a phase 2 trial of Amtagvi (lifileucel) for…
Scott Blanchard, PhD, co-corresponding author, St. Jude Department of Structural Biology The work built upon findings from a study the St. Jude team published in Nature in 2023, in which they used cryo-electron microscopy to determine the atomic structure of human…
Iovance Biotherapeutics, Inc. (IOVA) Discusses Positive Lifileucel Data and Precision TIL Strategy in Non-small Cell Lung Cancer October 29, 2026 8:30 AM EDT Sara Pellegrino - Senior Vice President of Investor Relations & Corporate CommunicationsFrederick Vogt - Interim CEO, President, General Counsel, Corporate Secretary & Director Lin…
2026-10-29. The following slide deck was published by Iovance Biotherapeutics, Inc. in conjunction with this event.
Why 2 Small Biotechs May Hold the Key to New Cancer Treatments At an Oct. 14, 2026, data cutoff, 17 of 69 patients in Cohorts 1 and 2 had responded to treatment, representing an objective response rate of about 25% under RECIST 1.1 criteria, according to Interim Chief Executive…
Data from the ongoing PULMO-01 clinical study to be presented on November 6, 2026, at SITC 2026 Roginolisib is the first conformation-selective PI3Kδ inhibitor that locks the enzyme in its inactive state CAMBRIDGE, Mass. and GENEVA and AMSTERDAM, Oct. 29, 2026 /PRNewswire/ -- iOnctura today announced that…
Northwestern Medicine scientists and collaborators have demonstrated a novel liquid biopsy technique that can measure cancer burden and reveal molecular characteristics of small cell lung cancer (SCLC), according to a new study published in the Journal of Clinical Investigation. The…
Lung cancer news: screening, new treatments and research, and why the disease is rising among people who never smoked.
An article joins this feed when it matches these terms. Each one is also a search of its own.